Identification of Immune Responses Against Aldehyde-Modified Peptide Sequences in ApoB Associated With Cardiovascular Disease
- 1 May 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 23 (5) , 872-878
- https://doi.org/10.1161/01.atv.0000067935.02679.b0
Abstract
Objective— Atherosclerosis is associated with an immune response against oxidized LDL, which modulates the progression of the disease process. Methods and Results— Using a library of polypeptides covering the complete sequence of apoB-100, the only major protein of LDL, we have identified over 100 different human antibodies reacting against aldehyde-modified apoB-100 sequences. IgM antibody titer levels decreased with age and were associated with the intima-media thickness of the carotid artery in subjects younger than 60 years. There were also inverse associations between IgM levels and oxidized LDL in plasma. In prospective clinical studies, antibody levels against several aldehyde-modified apoB-100 sites were associated with cardiovascular disease in this age group. Whether this immune response is adaptive (protective) or maladaptive (causal) in atherosclerosis requires further investigation. Conclusions— We have characterized a large number of epitopes within the apoB-100 component of oxidized LDL that provoke an immune response in humans. These findings will make it possible to study the role of immune responses against specific sites in oxidized LDL and to determine whether these immune responses influence the risk for future cardiac events.Keywords
This publication has 18 references indexed in Scilit:
- Ageing of lymphocytes and lymphocytes in the agedImmunology Today, 2000
- Inflammation and immune response in atherosclerosisCurrent Atherosclerosis Reports, 1999
- Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.Journal of Clinical Investigation, 1998
- Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis.Proceedings of the National Academy of Sciences, 1995
- Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteersInternational Journal of Clinical and Laboratory Research, 1993
- Autoantibody against oxidised LDL and progression of carotid atherosclerosisThe Lancet, 1992
- Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990
- Biochemical structural and functional properties of oxidized low-density lipoproteinChemical Research in Toxicology, 1990
- Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.Journal of Clinical Investigation, 1989
- Structure of apolipoprotein B-100 of human low density lipoproteins.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989